224 related articles for article (PubMed ID: 34266392)
1. Serum matrix metalloproteinase-13 as a diagnostic biomarker for cutaneous squamous cell carcinoma.
Wang H; Li H; Yan Q; Gao S; Gao J; Wang Z; Sun Y
BMC Cancer; 2021 Jul; 21(1):816. PubMed ID: 34266392
[TBL] [Abstract][Full Text] [Related]
2. Complement factor I upregulates expression of matrix metalloproteinase-13 and -2 and promotes invasion of cutaneous squamous carcinoma cells.
Rahmati Nezhad P; Riihilä P; Piipponen M; Kallajoki M; Meri S; Nissinen L; Kähäri VM
Exp Dermatol; 2021 Nov; 30(11):1631-1641. PubMed ID: 33813765
[TBL] [Abstract][Full Text] [Related]
3. Matrix Metalloproteinase-13 - A Potential Biomarker for Detection and Prognostic Assessment of Patients with Esophageal Squamous Cell Carcinoma.
Sedighi M; Aledavood SA; Abbaszadegan M; Memar B; Montazer M; Rajabian M; Gholamin M
Asian Pac J Cancer Prev; 2016; 17(6):2781-5. PubMed ID: 27356690
[TBL] [Abstract][Full Text] [Related]
4. MMP-7, MMP-8, and MMP-9 in oral and cutaneous squamous cell carcinomas.
Ahmed Haji Omar A; Haglund C; Virolainen S; Häyry V; Atula T; Kontio R; Salo T; Sorsa T; Hagström J
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Apr; 119(4):459-67. PubMed ID: 25697929
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma.
Zhou JH; Zhang B; Kernstine KH; Zhong L
World J Gastroenterol; 2011 Mar; 17(10):1373-8. PubMed ID: 21455340
[TBL] [Abstract][Full Text] [Related]
6. Circulating Anti-Matrix Metalloproteinase-7 Antibodies May Be a Potential Biomarker for Oral Squamous Cell Carcinoma.
Jiang T; Xie P; Liu H
J Oral Maxillofac Surg; 2016 Mar; 74(3):650-7. PubMed ID: 26454036
[TBL] [Abstract][Full Text] [Related]
7. Biomarker and Pathologic Predictors of Cutaneous Squamous Cell Carcinoma Aggressiveness.
Khandelwal AR; Ma X; Egan P; Kaskas NM; Moore-Medlin T; Caldito G; Abreo F; Gu X; Aubrey L; Milligan E; Nathan CA
Otolaryngol Head Neck Surg; 2016 Aug; 155(2):281-8. PubMed ID: 27095050
[TBL] [Abstract][Full Text] [Related]
8. p53-Regulated Long Noncoding RNA PRECSIT Promotes Progression of Cutaneous Squamous Cell Carcinoma via STAT3 Signaling.
Piipponen M; Nissinen L; Riihilä P; Farshchian M; Kallajoki M; Peltonen J; Peltonen S; Kähäri VM
Am J Pathol; 2020 Feb; 190(2):503-517. PubMed ID: 31837949
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic value of E-cadherin, MMP-9, activated MMP-13 and anti-p53 antibodies in squamous cell carcinomas of head and neck].
Al Kassam D; Alvarez Marcos C; Blanco I; de Los Toyos JR; Llorente JL
Med Clin (Barc); 2007 Dec; 129(20):761-5. PubMed ID: 18093475
[TBL] [Abstract][Full Text] [Related]
10.
Liu X; Guo R; Xu Y
Genet Test Mol Biomarkers; 2021 Jul; 25(7):463-470. PubMed ID: 34280008
[No Abstract] [Full Text] [Related]
11. The Expression Status and Prognostic Value of Cancer Stem Cell Biomarker CD133 in Cutaneous Squamous Cell Carcinoma.
Xu R; Cai MY; Luo RZ; Tian X; Han JD; Chen MK
JAMA Dermatol; 2016 Mar; 152(3):305-11. PubMed ID: 26560495
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of microRNA-20a promotes tumor progression and predicts poor prognosis of cutaneous squamous cell carcinoma.
Zhang L; Xiang P; Han X; Wu L; Li X; Xiong Z
Int J Clin Exp Pathol; 2015; 8(9):11446-51. PubMed ID: 26617873
[TBL] [Abstract][Full Text] [Related]
13. The Pathogenic Effect of Cortactin Tyrosine Phosphorylation in Cutaneous Squamous Cell Carcinoma.
Zhu L; Cho E; Zhao G; Roh MR; Zheng Z
In Vivo; 2019; 33(2):393-400. PubMed ID: 30804117
[TBL] [Abstract][Full Text] [Related]
14. C1r Upregulates Production of Matrix Metalloproteinase-13 and Promotes Invasion of Cutaneous Squamous Cell Carcinoma.
Viiklepp K; Nissinen L; Ojalill M; Riihilä P; Kallajoki M; Meri S; Heino J; Kähäri VM
J Invest Dermatol; 2022 May; 142(5):1478-1488.e9. PubMed ID: 34756877
[TBL] [Abstract][Full Text] [Related]
15. Overexpression and Implications of Melanoma-associated Antigen A12 in Pathogenesis of Human Cutaneous Squamous Cell Carcinoma.
Zhao G; Bae JY; Zheng Z; Park HS; Chung KY; Roh MR; Jin Z
Anticancer Res; 2019 Apr; 39(4):1849-1857. PubMed ID: 30952725
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of serum matrix metalloproteinase-13 levels in patients with esophageal squamous cell carcinoma (ESCC).
Jiao XL; Chen D; Wang JG; Zhang KJ
Eur Rev Med Pharmacol Sci; 2014; 18(4):509-15. PubMed ID: 24610617
[TBL] [Abstract][Full Text] [Related]
17. New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma.
Nissinen L; Farshchian M; Riihilä P; Kähäri VM
Cell Tissue Res; 2016 Sep; 365(3):691-702. PubMed ID: 27411692
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma.
Campos MA; Macedo S; Fernandes M; Pestana A; Pardal J; Batista R; Vinagre J; Sanches A; Baptista A; Lopes JM; Soares P
J Am Acad Dermatol; 2019 Mar; 80(3):660-669.e6. PubMed ID: 30165166
[TBL] [Abstract][Full Text] [Related]
19. An expression of squamous cell carcinoma antigen 2 in peripheral blood within the different stages of esophageal carcinogenesis.
Yang YF; Li H; Xu XQ; Diao YT; Fang XQ; Wang Y; Zhao DL; Wu K; Li HQ
Dis Esophagus; 2008; 21(5):395-401. PubMed ID: 19125792
[TBL] [Abstract][Full Text] [Related]
20. Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population-Based Data: A Nested Case-Control Study.
Roscher I; Falk RS; Vos L; Clausen OPF; Helsing P; Gjersvik P; Robsahm TE
JAMA Dermatol; 2018 Apr; 154(4):428-434. PubMed ID: 29516080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
